# Freespira

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/freespira

- Industry: Medical Devices & Equipment
- Headquarters: Kirkland, US
- Website: www.freespira.com
- Total disclosed funding: $20M
- Latest round: Series D (Dec 8, 2020)
- Investors on record: 4

## About

Freespira, Inc. provides innovative, non-medication solutions to effectively treat panic disorder and PTSD symptoms through a structured breathing regulation program.Founded in 2013 in Kirkland, US, Freespira, Inc. specializes in treatment for panic disorder and PTSD through a unique breathing regulation program. The company has undergone strategic developments to enhance its offerings but has no known subsidiaries. The firm was co-founded by Beth Siegelman, with Dean Sawyer and Joseph Perekupka currently serving as key executives. In April 2024, Freespira, Inc. raised USD 22.6 in venture funding from unspecified investors. Freespira offers an innovative, medication-free treatment specifically designed to address symptoms associated with panic disorder and post-traumatic stress disorder (PTSD) through a breathing regulation program. The core service includes two daily 17-minute sessions utilizing a small breathing sensor and a tablet that provides real-time feedback, complemented by training and weekly check-ins with a coach. This method is founded on the understanding that breathing irregularities and hypersensitivity to carbon dioxide are often linked to panic and PTSD symptoms, thus aiming to teach patients how to self-regulate their breathing patterns. Freespira's primary clientele includes individuals aged 13 and older suffering from anxiety and stress, with a significant focus on veterans and those experiencing trauma-related symptoms. The treatment is currently available in multiple geographical markets across the United States and Canada. Freespira's revenue generation model primarily revolves around a direct-to-consumer approach, where clients access treatment through a structured program that includes coaching and technological support. The firm engages customers via an all-inclusive package that encompasses the breathing sensor, tablet, and ongoing coaching sessions, establishing a comprehensive service offering tailored to meet the needs of its users. The program is designed to deliver lasting results within a 28-day treatment window, focusing on patient outcomes and evidence-based results. Freespira aims to enhance its product offerings and expand into new markets following its recent funding. In April 2024, Freespira, Inc. raised USD 22.6 in venture funding from unspecified investors.

## Funding rounds

- Series D, Dec 8, 2020, $10M — Lightspeed Venture Partners, Aphelion Capital, Medvest Capital
- Series D, Oct 26, 2020, $9.1M — Lightspeed Venture Partners
- Seed, Sep 24, 2013, $1.2M — Kleiner Perkins

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Seed
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series D
- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series D
- Medvest Capital (https://capitalatlas.ai/funds/medvest-capital) — Series D